CompletedNCT00816894
What is this study about?Researchers compared D-serine and Olanzapine to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
In JerusalemSchizophreniaMedication studyAges 18–70
- Countries
- Israel
- Sponsor
- Herzog Hospital
CompletedNCT01390376
This study has finished and is no longer accepting participants.
In TaichungSchizophreniaMedication studyAges 18–65
- Countries
- Taiwan
- Sponsor
- China Medical University Hospital
CompletedNCT02532686
This study has finished and is no longer accepting participants.
In TaichungSchizophreniaMedication studyAges 18–65
- Countries
- Taiwan
- Sponsor
- China Medical University Hospital
TerminatedNCT01712646
Official study titleThe Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial
This study ended early.
In BethesdaSchizophreniaMedication studyAges 10–99
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH) (Government agency)
CompletedNCT01041274
Official study titleCitalopram in First Episode Schizophrenia
This study has finished and is no longer accepting participants.
In New YorkSchizophrenia, DepressionMedication studyAges 16–40
- Countries
- United States
- Sponsor
- NYU Langone Health
CompletedNCT02187835
Official study titleDecreased EEG Complexity in Chronic Residual Schizophrenia
This study has finished and is no longer accepting participants.
In IstanbulSchizophreniaObservational studyAges 18–65
- Countries
- Türkiye
- Sponsor
- Uskudar University
WithdrawnNCT01725334
Official study titleDeep Brain Stimulation for the Management of Treatment Refractory Negative Symptoms in Schizophrenia
This study was withdrawn before enrollment.
In TorontoSchizophreniaInterventional studyAges 25–60
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT01689389
Official study titleDescription of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France
This study has finished and is no longer accepting participants.
Multiple locations, including ArgenteuilSchizophrenia, BipolarityObservational studyAges 18–130
- Countries
- France
- Sponsor
- AstraZeneca
CompletedNCT04754750
Official study titleDifferences in Lipid and Cognitive Change Between One-month and 3-month Paliperidone Palmitate Treatment in Stable Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 30–69
- Countries
- Sponsor
- Calo Psychiatric Center
CompletedNCT00501163
This study has finished and is no longer accepting participants.
In St LouisSchizophreniaObservational studyAges 10–55
- Countries
- United States
- Sponsor
- Washington University School of Medicine
CompletedNCT00573300
Official study titleDisturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative RT-PCR Study
This study has finished and is no longer accepting participants.
In BostonSchizophreniaObservational studyAges 18–65
- Countries
- United States
- Sponsor
- North Suffolk Mental Health Association
CompletedNCT01312272
This study has finished and is no longer accepting participants.
In Los AngelesSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- VA Greater Los Angeles Healthcare System